Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal ...

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...

Melinda Bachini is the Chief Patient Officer at the Cholangiocarcinoma Foundation and a 15-year survivor of ...

A survey of the nation's oncologists showed that professional burnout has reached a new high (59% vs 45% in 2013), and fewer ...

That is about to change, with $6 million awarded to National Cancer Centre Singapore (NCCS) senior consultant surgeon Pierce ...

The firm will make its artificial intelligence-based Lunit SCOPE IO platform available to SITC member researchers.

San Diego, USA-based Turnstone Biologics yesterday announced that it has completed an assessment of its business and ...

A spokesperson for the Cholangiocarcinoma Foundation writes that experimental cancer trials saved her life and could save the ...

Turnstone Biologics Corp. ("Turnstone" or the "Company") (Nasdaq: TSBX) today announced that it has completed an assessment of its business and operations ...

Turnstone, which went public via an $80 million IPO in 2023, ended September 2024 with $45.3 million to hand, which the ...